Page 2 - Mark Gergen News Today

P-MUC1C-ALLO1 and P-BCMA-ALLO1 were well tolerated, with no dose-limiting toxicities (DLTs), cytokine release syndrome (CRS), graft vs host disease (GVHD) or...

/PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with...

Poseida announced a strategic global collaboration agreement with Roche potentially worth up to $6 billion. See why I feel PSTX stock appears undervalued.

Aristea Therapeutics Strengthens its Board of Directors with the Appointment of Three Accomplished Biopharma Leaders From Poseida Therapeutics, Novo Holdings and Pfizer - read this article along with other careers information, tips and advice on BioSpace

San Francisco District Attorney Brooke Jenkins’ disclosure caused controversy because she said she worked on Chesa Boudins recall in a volunteer capacity.

/PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform...

Leveraging Poseidas novel approach to cell therapy and Roches expertise in developing and commercializing therapies to transform cancer care, the...

Poseida Therapeutics Appoints Charles M. Baum, M.D., Ph.D., to Board of Directors - read this article along with other careers information, tips and advice on BioSpace

/PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform...

SAN DIEGO, March 10, 2022 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing propriet...